Recruiting

A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer

The purpose of this study is to find out if Meaning-Centered Psychotherapy for Latinos (MCP-L) helps reduce anxiety and depression and improves quality of life compared to cognitive behavioral therapy (CBT). Investigators also want to learn what participants and providers think about the therapy, including how the therapy is designed, outside factors, available resources, and how the people involved affect how well MCP-L works.

ClinicalTrials.gov IDNCT07225309
PhaseNA
Enrollment300
SponsorMemorial Sloan Kettering Cancer Center
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Breast Cancer, Prostate Cancer, Colorectal Cancer, Thyroid Cancer, Breast Cancer Stage III, Breast Cancer Stage IV, Prostate Cancer Stage III, Prostate Cancer Stage IV, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Thyroid Cancer Stage III, Thyroid Cancer Stage IV

About this study

The purpose of this study is to find out if Meaning-Centered Psychotherapy for Latinos (MCP-L) helps reduce anxiety and depression and improves quality of life compared to cognitive behavioral therapy (CBT). Investigators also want to learn what participants and providers think about the therapy, including how the therapy is designed, outside factors, available resources, and how the people involved affect how well MCP-L works.

Interventions

Primary outcomes

Eligibility information

Patient Eligibility Criteria: A patient cannot be considered eligible for this study unless ALL of the following conditions are met. Participant eligibility will be determined by an initial EMR review followed by a self-report screener and suicide risk assessment. Inclusion Criteria: EMR Criteria \- Documentation of Disease * Pathologically confirmed breast, prostate, colorectal, thyroid, cervix, uteri, or lung - solid tumor cancer (either most recent or new diagnosis) * Definition of Disease \[or Measurable Disease\] * Diagnosed with stages III or IV * Prior Treatment * Receiving ambulatory care at INCan Self-Report Criteria * Age ≥ 18 years * Able to read and communicate in Spanish determined by the question: "Can you read and communicate in Spanish? Yes/No" * Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention * Providing care (or services) to Mexican cancer patients at INCan * Has access to internet and an electronic device * Agrees to be audio-recorded Exclusion Criteria: EMR Criteria * Prior Treatment * Received psychological or psychiatric care at INCan in the last 3 months * In the judgment of the treating physician, protocol investigators, and/or study staff, presence of cognitive impairment (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and/or study participation * Diagnosed with a serious psychiatric condition Self-Report Criteria * Received psychological or psychiatric care outside of INCan in the last 3 months * Presence of suicide risk determined by the Columbia-Suicide Severity Rating Scale * Too ill to participate determined by the question: "Do you feel too ill to participate because of communication problems, uncontrollable pain, or other symptoms that prevent you from participating?" Provider Eligibility Criteria: Inclusion Criteria Self-Report Criteria * Age ≥ 18 years * Able to read and communicate in Spanish determined by the question: "Can you read and communicate in Spanish? Yes/No" * Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention * Providing care (or services) to Mexican cancer patients at INCan * Has access to internet and an electronic device * Agrees to be audio-recorded

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.